The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)

Table 1

General information of the study.

Variable	Control group		Study group
		%		%
Gender
Male	1	3.85%	0	0%
Female	25	96.15%	11	100%
Mean age (years)	70.69 ()		74.81 ()
Type of medication used
Alendronate	12	46.15%	7	63.64%
Risedronate	5	19.23%	1	9.09%
Ibandronate	2	7.69%	0	0%
Denosumab	2	7.69%	1	9.09%
	2	7.69%	0	0%
	2	7.69%	0	0%
	1	3.85%	2	18.18%
Type of disease
Osteoporosis	14	53.85%	5	45.45%
Oncological disease	12	46.15%	6	54.55%
Route of drug therapy
Oral	22	84.59%	10	90.91%
Intravenous	2	7.69%	0	0%
Subcutaneous	2	7.69%	1	9.09%
Mean duration of drug therapy (months)
Oral	44.18 ()		59.20 ()
Intravenous	56 ()		—
Subcutaneous	49 ()		37
Risk level associated to CTX value
High risk; CTX level less than 100 pg/mL	6	23.07%	4	36.36%
Moderate risk; CTX level between 100 and 150 pg/mL	5	19.23%	3	27.27%
Low risk; CTX level above 150 pg/mL	15	57.69%	4	36.36%
Tooth extracted
Mandible	27	64.28%	18	66.67%
Maxilla	15	35.71%	9	33.33%
Reason for extraction
Periodontitis	8	19.04%	7	25.9%
Destructive tooth decay	11	26.19%	11	40.7%
Residual roots	23	54.76%	9	33.3%
Other risk factors
Diabetes	4	15.38%	1	33.33%
Smoking habits	5	19.23%	2	66.67%